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Abstract: Syphilis is a resurgent sexually transmitted infection in the UK which is 
disproportionately diagnosed in patients living with HIV, particularly men who have sex with 
men. Evidence exists to suggest that syphilis presents differently in patients with HIV, 
particularly in those with severe immunosuppression. Progression to neurosyphilis is more 
common in HIV co-infection and can be asymptomatic, often for several years. Symptoms of 
neurosyphilis vary but can include meningitis, meningovascular disease, general paresis and 
tabes dorsalis. Debate exists surrounding in which circumstances to perform a lumbar puncture 
and the current gold standard diagnostics have inadequate sensitivity. We recommend a 
pragmatic approach to lumbar punctures, interpretation of investigations, and when to consider 
treatment with a neuropenetrative antibiotic regimen. 
 
THE CHANGING FACE OF SYPHILIS 
Syphilis, caused by the spirochaete bacterium Treponema pallidum, has seen a resurgence in 
high-income countries in recent years, particularly among men who have sex with men(1). The 
widespread availability of penicillin in the United States and other industrialised countries 
following World War Two resulted in rates of syphilis falling from 76 per 100,000 population 
in 1945 to 4 per 100,000 in 1955-57. After this period syphilis became concentrated within 
men who have sex with men and incidence surged during the 1980s HIV/AIDS epidemic(1). 
In response to the fear induced by the epidemic, changes in sexual behaviour caused another 
decline until recently where rates have risen rapidly again(1, 2). In the United States during 
2014-2015 syphilis occurred in 7.5 cases per 100,000, the highest rate since 1994(3). Similar 
trends were seen in England where in 2016 the number of cases was 5920 (Figure 1)(4), 12% 
higher than the previous year and the highest number of new diagnoses since 1949, with 80.9% 
of cases reported in men who have sex with men(2).   
 
SYPHILIS INFECTION 
Syphilis infection involves a number of stages. Primary syphilis classically presents 9-90 days 
after infection with a single, non-tender genital ulcer called a chancre which represents the first 
site of T.pallidum invasion. If untreated, primary infection progresses to secondary syphilis, 
typically 12 weeks, but sometimes up to 12 months after initial infection. The classic 
presentation of secondary syphilis is a rash which typically involves the trunk, may involve the 
hands or feet and may be accompanied by condylomata lata, wart-like lesions around the 
anogenital region. Latent syphilis results when both primary and secondary syphilis are not 
treated and is defined by serological proof of infection but no symptoms. It is divided into early 
and late latent syphilis, with early latent syphilis infectious and late latent syphilis, defined in 
the UK as more than two years after infection, found to generally be non-infectious (5, 6).  
 
Syphilis will progress to tertiary disease in one third of patients without treatment roughly 20-
40 years after primary infection(5). Tertiary syphilis involves a severe and self-destructive 
 3 of 16 
immune response to a persistent low level burden of T. pallidum(5). This can present as 
cardiovascular syphilis, gummatous syphilis, late benign syphilis or neurosyphilis(6). It is 
important to emphasise that neurological symptoms can occur during any phase of infection 
and therefore neurosyphilis should only be considered tertiary when presenting in the late-
latent period(5). Primary, secondary and early latent syphilis are collectively grouped together 
as early syphilis and late latent and tertiary syphilis are grouped together as late syphilis. 
 
NEUROSYPHILIS 
Neurosyphilis is a broad term used to describe the direct invasion of T pallidum into the nervous 
system and can affect the brain, spinal cord and peripheral nerves(7). Approximately 25-40% 
of patients will have ‘neuroinvasion’ at some point, typically during the primary or secondary 
stage of infection, but the majority will spontaneously clear the infection from the cerebrospinal 
fluid (CSF) without requiring treatment for neurosyphilis and potentially without having any 
symptoms(8). In patients whose immune system is unable to clear the infection, neurosyphilis 
will occur and this can also present with or without symptoms, the latter form known as 
asymptomatic neurosyphilis(7). There exists great debate around the topic of asymptomatic 
neurosyphilis which is discussed below. 
 
Syphilis is often referred to as ‘the great imitator’ and it can present in countless ways. The 
clinical manifestations of neurosyphilis are similarly varied and patients may remain 
asymptomatic for years. Levels of central neurological involvement can be classified into 
meningeal, vascular or parenchymatous forms with direct invasion of T. pallidum possible at 
each of these sites (9). Meningeal and vascular neurosyphilis are inflammatory processes which 
frequently coexist (meningovascular neurosyphilis), particularly in the early years of 
infection(10). Meningeal involvement can present as aseptic meningitis with symptoms such 
as headache, photophobia and neck stiffness and can lead to complications such as cranial nerve 
palsies(9). Vascular syphilis can affect the arterial supply of the brain or spinal cord resulting 
in ischaemic stroke and, depending on the arterial territory involved, can cause different 
neurological deficits. Neurosyphilis should therefore always be considered as a differential 
diagnosis in any patient with ischaemic stroke of unknown aetiology, particularly in young 
people(9). Parenchymal neurosyphilis is neurodegenerative in nature and can manifest as 
general paresis characterised by memory deficit, emotional lability, psychosis or tabes dorsalis 
(also known as syphilitic myelopathy) in which patients may develop sensory ataxia and 
neuropathic pain in the lower limbs(11, 12). Parenchymal changes tend to arise years to 
decades after initial infection and due to the widespread availability and prescribing of 
penicillin are now extremely rare(11, 13). A fourth, distinct and rare form of central 
neurosyphilis can emerge in gummatous syphilis which causes space occupying lesions which 
may result in seizures, focal neurological signs, raised intracranial pressure or progressive 
paraparesis or quadriparesis(9). Involvement of the peripheral nervous system is not the focus 
 4 of 16 
of this review and is less common but can include polyradiculopathy and peripheral 
neuropathy(14). 
 
THE SYNERGISTIC RELATIONSHIP BETWEEN HIV AND SYPHILIS 
HIV and syphilis affect similar patient groups and in 2002 the United States Center for Disease 
and Control Prevention (CDC) reported the incidence of syphilis to be 77 times greater in HIV 
infected individuals than that of the general population(15). This is of particular significance 
because HIV and syphilis have a synergistic relationship wherein syphilis can increase the risk 
of HIV transmission and acquisition whilst HIV can affect the presentation, diagnosis, 
progression and treatment response of syphilis(16). A large body of the evidence related to this 
is presented in the context of advanced HIV and might not apply to those with CD4 counts ≥ 
350 cells/µL and/or a suppressed HIV viral load. 
 
In terms of HIV acquisition, syphilis causes transient immunosuppression and can weaken the 
host response to HIV, increasing the likelihood of exposure leading to HIV infection. In 
addition to this, chancres are particularly vulnerable, well vascularised sites for HIV to enter 
the bloodstream and establish primary infection(17, 18). 
 
The impact of HIV on syphilis is explained by the immunodeficiency caused by HIV and the 
presentation of syphilis may be more severe or atypical, particularly in the severely 
immunosuppressed. These individuals are more likely to develop multiple, deeper or larger 
chancres and can have primary and secondary infection overlap(19). This trend continues in 
the context of neurosyphilis: A review of syphilis cases in Los Angeles between 2001 and 2004 
showed a 2.1% incidence of neurosyphilis among those infected with HIV compared to 0.6% 
among those without HIV(20). The likelihood of developing neurosyphilis has been linked to 
the degree of immunosuppression caused by HIV with it being suggested that patients with a 
CD4 count of ≤ 350 cells/µL have a 3-fold increase in neurological involvement(21). 
 
ASYMPTOMATIC NEUROSYPHILIS 
Asymptomatic neurosyphilis is a topic of significant debate and scientific uncertainty. 
Concerns arose from studies which reported a greater level of neurocognitive impairment in 
HIV positive patients with previous early-syphilis but no diagnosis of neurosyphilis who were 
treated with standard Benzathine Penicillin G, which does not cross the blood-brain barrier, 
when compared to those without previous syphilis. Unfortunately these studies did not consider 
confounding factors such as alcohol consumption, smoking history, CD4 count, HIV viral load, 
recreational drug use and other co-infections(22, 23). 
 
It is known that both pathogens can cause meningeal inflammation, leading to increased CSF 
penetration by the other infectious agent. Patients with concurrent HIV and syphilis infections 
have been found to have a higher CSF HIV viral load(17) which itself is known to be associated 
with neurocognitive impairment(17, 24). A recent prospective study found no association 
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between neurosyphilis and cognitive impairment in HIV positive individuals but did identify 
significantly higher levels of inflammatory markers that are associated with the development 
of cognitive impairment in the CSF of patients with neurosyphilis(25). 
 
A study in the UK of 64 HIV positive patients with early syphilis that were treated with a single 
dose of Benzathine Penicillin G found that the risk of asymptomatic neurosyphilis was unlikely 
as only one patient developed asymptomatic neurosyphilis, as determined by CSF 
parameters(26). This contrasts with a study in the USA which found rates of asymptomatic 
neurosyphilis of 22% among 46 HIV positive, asymptomatic patients who underwent lumbar 
puncture(27). These differing rates of asymptomatic neurosyphilis likely reflect levels of 
immunosuppression, anti-retroviral therapy status, and severity of syphilis infection. The 
knowledge that syphilis causes neuro-inflammation in HIV infection, coupled with 
uncertainties surrounding the prevalence, clinical significance, and optimal treatment of 
asymptomatic neurosyphilis has left clinicians uncertain about whether all HIV positive 
patients should either undergo a lumbar puncture and/or be treated with a neuropenetrative 
antibiotic regimen.  
 
DIAGNOSIS OF NEUROSYPHILIS 
The presence of syphilis infection and neurological symptoms should raise significant 
suspicion of neurosyphilis. The following investigations must be interpreted with an 
understanding of their limitations and in the context of the clinical picture. 
 
Microscopy 
Genital syphilis can be diagnosed by swabbing a chancre and performing dark ground 
microscopy which will reveal the presence of T. pallidum(5). This technique is still used in 
genitourinary medicine clinics and can be used on samples obtained from biopsies, including 
in suspected cases of neurosyphilis. 
 
Blood Tests 
Syphilis can be difficult to diagnose due to the several weeks delay between exposure and 
seroconversion. When suspected, patients are screened with an enzyme linked immunosorbent 
assay (EIA) (Table 1). Other treponemes which affect humans include the endemic 
treponematoses bejel (Treponema pallidum subsp. endemicum) and yaws (Treponema 
pallidum subsp. pertenue) so a positive test will need to be taken in the context of the clinical 
picture and history(28). A confirmatory test called the T. pallidum haemagglutination (TPHA) 
or T. pallidum particle agglutination (TPPA) is then performed although in some settings this 
may be the only treponemal-specific test performed. EIA, TPHA and TPPA remain positive 
for life. In individuals with a positive TPHA/TPPA either a venereal disease research 
laboratory (VDRL) or reactive plasma reagin test (RPR) is carried out: these detect anti-
cardiolipin antibodies in the blood and are given as a titer which is used to assess burden of 
infection, monitor response to treatment and diagnose treatment failure or re-infection(5, 28). 
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Table 1: How to interpret syphilis serology 
 EIA IgG/IgM TPPA or TPHA VDRL or RPR 
Never - - - 
Early + + - 
Secondary + + + 
Late + + - 
Treated + + - 
Reinfected + + + 
False Positive EIA + - - 
False Positive TPPA/TPHA - + - 
False Positive RPR - - + 
EIA: Enzyme-linked immunosorbent assay, RPR: Rapid plasma reagin, TPHA: Treponema 
pallidum haemagglutination, TPPA: Treponema pallidum particle agglutination, VDRL: 
Venereal disease research laboratory. 
 
CSF Analysis 
Diagnosis of neurosyphilis with CSF analysis is often difficult. CSF abnormalities include 
elevated white blood cell (WBC) count (with predominance of lymphocytes), elevated protein 
and a reactive CSF-VDRL or RPR. These CSF abnormalities must be taken in the context of 
the clinical findings (6, 29). Headache and visual disturbance have been strongly associated 
with symptomatic neurosyphilis in HIV positive individuals however, as described earlier, the 
manifestations are extremely variable and these symptoms are non-specific(9).  Neurological 
symptoms and signs must be sought with extreme care in patients with syphilis and HIV co-
infection and the possibility of asymptomatic neurosyphilis must be appreciated(30). In 
asymptomatic individuals diagnosis is based on CSF abnormalities alone and these may be less 
marked(9). Neurosyphilis may be the first presentation in a patient with HIV so all patients 
diagnosed with neurosyphilis should be tested for HIV.  
 
Several clinical and laboratory parameters are used to aid the diagnosis of neurosyphilis in the 
context of HIV and are of use when deciding which patients should undergo CSF examination 
and receive enhanced treatment with a neuropenetrative regimen (Tables 2 and 3). There is 
consensus that in the presence of neurological symptoms such as headache or altered mental 
state a CSF analysis should be performed regardless of laboratory parameters. Indications for 
CSF analysis in patients who are asymptomatic however, have been debated. European and 
Canadian guidelines state that patients with a CD4 count of ≤350 cells/µL or a VDRL/RPR 
titer of ≥1:32 should undergo lumbar puncture although this differs from the CDC 
recommendation (31, 32). Ghanem et al found these criteria to be most reliable in identifying 
asymptomatic neurosyphilis(27). The lack of systematic research into this area contributes to a 
lack of consensus on which patients will benefit from screening and enhanced treatment for 
neurosyphilis. 
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Table 2: Indications for a lumbar puncture 
Neurological signs 
Ocular involvement 
CD4 count <350 cells/µL* 
VDRL/RPR titer >1:32* 
ART naïve* 
* consider 
 
Table 3: Factors suggesting a diagnosis of neurosyphilis: 
Neurological signs 
Ocular involvement 
Positive CSF test including: VDRL, RPR, TPHA, TPPA, PCR 
CSF pleocytosis: >20 cells if ART naïve, >10 cells if ART exposed 
 
ART: Antiretroviral therapy, CSF: cerebrospinal fluid, PCR: Polymerase chain reaction, RPR: 
Rapid plasma reagin, TPHA: Treponema pallidum haemagglutination, TPPA: Treponema 
pallidum particle agglutination, VDRL: Venereal disease research laboratory. 
 
The CSF-VDRL is the ‘gold standard’ in terms of specificity for neurosyphilis but has 
significant limitations: Its variable sensitivity (30%-70%) means a non-reactive CSF-VDRL 
does not exclude the diagnosis of neurosyphilis. However as CSF-VDRL is highly specific a 
reactive CSF-VDRL confirms the diagnosis(33). CSF-RPR is easier to perform but has lower 
sensitivity than VDRL(34). CSF treponemal tests such as the TPPA can be used in conjunction 
with VDRL as they are highly sensitive but non-specific therefore a negative treponemal test 
excludes the diagnosis of neurosyphilis. Some studies suggest high-titer CSF TPPA results are 
more specific for neurosyphilis(6, 33). CSF polymerase chain reaction (PCR), although not 
widely available, has sensitivity of 70-76% and a specificity of 87-92%(35). 
 
Even in centres where each of these tests is available the results can often be inconclusive and 
the diagnosis may be made on CSF pleocytosis alone. Challenges arise here as HIV itself can 
cause CSF pleocytosis(9). Patients with neurosyphilis generally have a CSF WBC count >10 
cells/µL however if a HIV positive patient has positive syphilis serology and a non-reactive 
CSF-VDRL a cut off of >20 cells/µL is often used(29). Clinicians need to be cautious when 
deciding an appropriate cut off as patients on ART and/or with an undetectable plasma HIV 
viral load are less likely to have CSF pleocytosis and therefore the lower cut off of >10 cells/µL 
might still be appropriate in this group. It is however still unclear as to whether the pleocytosis 
is due to syphilis, HIV, a combination of both or an alternative diagnosis so CSF pleocytosis 
is a poor diagnostic tool for neurosyphilis(29). A raised protein >0.45g/l may also suggest 
neurosyphilis but again lacks specificity(36).  
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This lack of an ideal diagnostic test has prompted research into new CSF diagnostic markers. 
The B lymphocyte chemoattractant chemokine CXCL13 has proven to be the most promising 
and could be used independent of CSF pleocytosis and CSF-VDRL(37). Levels decline after 
treatment so CXCL13 could potentially also be used as a marker of treatment response(38). If 
CXCL13 is to be used in clinical practice its sensitivity and specificity needs to be established 
and recommended cut off parameters identified(38). 
 
NEUROIMAGING 
Imaging can sometimes be helpful in the diagnosis and monitoring of neurosyphilis, although 
there are no abnormalities which are specific for the condition and scans can be normal. Owing 
to the meningovascular inflammation predominantly involving small to medium-sized vessels, 
areas of infarction or haemorrhage are perhaps most commonly observed, and often said to be 
within the middle cerebral and basilar artery territories, along with meningeal enhancement, 
non-specific white matter lesions and mild generalized atrophy (Figures 2 and 3)(39,40).  scan 
can Magnetic Resonance Imaging (MRI) is preferred over Computed tomography (CT) given 
the superior parenchymal resolution and characterization of potential posterior fossa or spinal 
cord involvement. CT, MRI or even formal catheter angiography may be indicated to 
demonstrate vessel narrowing or irregularity particularly when alternative diagnoses such as 
non-infectious cerebral vasculitides are suspected(39, 41).  
 
DIFFERENTIAL DIAGNOSIS 
Neurosyphilis should be a differential diagnosis for any HIV positive patient presenting with 
unexplained neurological symptoms as listed in Table 4(11). Challenges arise due to the 
overlap of neurological manifestations caused by both organisms and the numerous pathologies 
which can be seen in advanced HIV infection. Either organism can independently cause acute 
or chronic meningitis, vasculitis, cranial neuropathies, cognitive decline, myelopathy and 
peripheral neuropathies(42). All HIV positive patients with neurological symptoms, including 
cognitive impairment, should be subject to an appropriate diagnostic workup to rule out 
common viral infections (particularly herpes simplex, varicella zoster, enterovirus), 
cryptococcal meningitis, tuberculosis, toxoplasmosis, lymphoma, progressive multifocal 
leucoencephalopathy and a detectable HIV viral load causing HIV encephalitis(13). 
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Table 4: Potential manifestations of Neurosyphilis 
(Aseptic) meningitis 
Chronic headache  
Psychiatric illness 
Cognitive impairment 
Ischaemic stroke 
Seizures 
Mass lesion 
Cranial (poly)neuropathy 
Optic neuritis/optic atrophy 
Ataxia 
Transverse myelitis  
Myelopathy 
(Poly)radiculopathy 
Peripheral neuropathy  
 
TREATMENT 
Penicillins remain the treatment of choice for all stages of syphilis with no penicillin resistance 
described. Guidelines currently recommend that, in the absence of central nervous system 
involvement, early (primary, secondary, and early latent) syphilis should be treated with a 
single dose of Benzathine Penicillin G (BPG) 2.4 million units (MU) intramuscularly (IM) and 
late latent syphilis should be treated with 3 doses BPG 2.4 MU IM at 1 week intervals, 
regardless of HIV status (Table 5) (6). Although this is the first-line recommended regimen a 
large review found that in HIV positive patients it is associated with serological failure (defined 
as a less than four-fold decline in RPR/VDRL titer) in between 0 and 33% of cases. This risk 
is reduced by roughly 60% with the use of antiretroviral therapy(17).  
 
Table 5: Treatment regimen options for different stages of syphilis: 
Early disease (<2yrs, 
primary, secondary, early 
latent) 
a) BPG 2.4 MU IM stat 
b) Doxycycline 100mg BD for 14 days 
 
 
Late latent disease (>2yrs)  
Tertiary, cardiovascular or 
gummatous 
a) BPG 2.4 MU IM, 3 doses at weekly intervals 
b) Doxycycline 100mg PO BD for 28 days 
c) Amoxicillin 500mg PO QDS plus Probenecid 500mg 
PO QDS for 28 days 
 
Neurosyphilis a) Procaine penicillin 2.4 MU IM plus Probenecid 
500mg PO QDS for 10-14 days 
b) Benzylpenicillin 10.8-14.4g daily given as 1.8-2.4g 
IV every 4 hours for 10-14 days 
c) Doxycycline 200mg PO BD for 28 days 
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d) Amoxicillin 2g PO TDS plus Probenecid 500mg PO 
QDS for 28 days 
e) Ceftriaxone 2g IM or IV OD for 10-14 days 
BD: Twice daily, BPG: Benzathine Penicillin G, IM: Intramuscular, IV: Intravenous, OD: 
Once daily, PO: Oral, TDS: Three times daily, QDS: Four times daily. 
 
In patients for whom the diagnosis of neurosyphilis is established, treatment success is 
dependent upon patients reaching sustained treponemicidal penicillin levels in the CSF. To 
ensure CSF penetration, neurosyphilis is treated with an intensified regimen of 1-8-2.4 MU 
procaine penicillin given intramuscularly once daily for 10-14 days with oral probenecid 
500mg four times a day. Alternatively, inpatient treatment can be given with benzyl penicillin 
10.8-14.4g in total daily dose, given as 1.8-2.4g intravenously every 4 hours for 10-14 days to 
those who are acutely unwell(6). In our centre in Brighton all co-infected patients are treated 
with procaine penicillin regardless of whether either a lumbar puncture has been performed or 
neurosyphilis diagnosis has been confirmed because of the concern of asymptomatic 
neurosyphilis. At this site, Warwick et al. reported high serological treatment success rates at 
98% at 6 months as well as good patient adherence despite the prolonged course of 
intramuscular treatment(43). A global shortage of probenecid however makes it unfeasible to 
presumptively treat patients for neurosyphilis without CSF analysis. 
 
If a patient with neurosyphilis has significant penicillin allergy, penicillin desensitisation is 
thought to be the best option(31, 32, 44). When penicillin based regimens are not available 
doxycycline 200mg twice per day for 28 days is recommended(6). Due to its tolerability and 
resistance concerns erythromycin and azithromycin are no longer recommended particularly in 
men who have sex with men where syphilis is highly prevalent(45).  A small observational 
study reported that ceftriaxone 1 to 2g per day intramuscularly for 10 days is an effective 
alternative to penicillin however evidence is limited(46).  High dose oral amoxicillin plus oral 
probenecid has also proven to be highly effective in a retrospective observational study of 
patients with early and late syphilis and HIV infection (47).  
 
Steroids and the Jarisch-Herxheimer Reaction 
The Jarisch-Herxheimer reaction is an acute pyrexial illness with associated headaches, 
myalgia and rigors which is commonly experienced by patients several hours after initiating 
treatment. This is a pro-inflammatory response caused by the destruction of large volumes of 
treponemes and is seen particularly among those with high VDRL/RPR titers. Guidelines 
recommend that patients with neurosyphilis be prescribed three days of oral prednisolone 
40mg: 24 hours before and 48 hours after commencing syphilis treatment(48). Although data 
is limited it appears that steroids do not reduce the incidence of the reaction but may reduce 
the severity(6). Given that steroids have little or no effect on symptomatic neurological 
sequelae and are known to cause immunosuppression it is safer not to prescribe them to 
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immunosuppressed patients. The only caveat to this is in cases of ocular syphilis where 
worsening of symptoms, which may not be reversible, can be caused by a Jarisch-Herxheimer 
reaction and therefore the prescription of steroids should be considered. In cases of advanced 
immunosuppression seek guidance from a HIV specialist when considering prescribing 
steroids. 
 
OCULAR SYPHILIS 
Syphilis can affect the eyes in a multitude of ways. Conceivably the most well remembered 
ocular manifestation is the Argyll Robertson pupils which accommodate but do not react to 
light and thus demonstrate light-near dissociation. This finding is highly specific for syphilis 
but can also be seen in diabetic neuropathy or as part of a dorsal midbrain syndrome. Anterior 
or posterior uveitis is perhaps most commonly encountered but papillary conjunctivitis, 
scleritis, neuroretinitis and retinal vasculitis are also observed, usually in secondary and tertiary 
stages. Furthermore, syphilis is on the important list of differential diagnoses for presentations 
of progressive optic neuropathy, and thus should be excluded in patients whose optic neuritis 
is ‘atypical’. Ocular syphilis is considered to be a type of neurosyphilis, although it is not 
always accompanied by syphilitic meningitis or abnormal CSF results. However, given that the 
recommended treatment is the same neuropenetrative regimen used for neurosyphilis(48), it 
may not be necessary to perform CSF analysis in every case. 
 
MONITORING 
Patients who have been treated for neurosyphilis should have their blood RPR/VDRL titers 
monitored on a three-monthly basis with serological response defined as a four-fold decline in 
titer or reversion to a seronegative state(6). Patients with HIV may demonstrate a slower time 
to serological response of up to 12 months due to loss of immune function such that there is a 
low-level production of antibodies. In patients with serological failure - a less than four-fold 
decline in titer, static titer or increase in titer - a thorough history and examination should be 
conducted to determine whether this could be due to treatment failure or re-infection. It may 
be necessary to perform repeat CSF analysis in this situation(49). 
 
Repeat lumbar puncture should also be performed if significant CSF pleocytosis (>10 cells/µL) 
or positive CSF-VDRL were present at initial CSF examination. CSF examination should be 
repeated at least six-monthly until the cell count is normal but may be necessary more 
frequently depending on the clinical picture. Repeat CSF examination may also demonstrate 
reduction in the CSF-VDRL concentration as a result of treatment, but these changes occur 
slowly and persistent abnormalities may not necessarily suggest treatment failure. If a 
pleocytosis persists after six months, without alternative explanation, re-treatment is 
advised(50).  
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FUTURE RESEARCH 
Further research is required to determine to what extent previous or ongoing syphilis infection 
in people living with HIV contributes to neurocognitive decline and which patients with HIV 
and syphilis co-infection should be actively investigated for neurosyphilis. Comparison of 
serological and clinical outcomes of patients with HIV and early syphilis treated with single-
dose Benzathine Penicillin G compared to the neuropenetrative procaine penicillin regimen is 
needed. More research is also required to validate improved diagnostic markers such as 
CXCL13.  
 
Case One: 
A 42 year old HIV positive man presents to a sexual health clinic with a primary chancre and 
evidence of T.pallidum on dark ground microscopy. His most recent CD4 count is 55 
cells/µL and he is not on antiretroviral therapy. Neurological examination including 
fundoscopy is normal.  
 
This man should certainly be offered a lumbar puncture. He is at high risk of neurosyphilis as 
well as other opportunistic infections that can cause meningoencephalitis. If the lumbar 
puncture identifies WBC <10 cells/µL and a negative CSF-VDRL then you can be confident 
he does not have neurosyphilis. If he refuses a lumbar puncture then commence outpatient 
treatment with a neuropenetrative regimen such as procaine penicillin with probenecid for 14 
days or doxycycline for 28 days. It is not advisable to give steroids to someone with this level 
of immunosuppression. 
 
Case Two: 
A 26 year old HIV positive man presents with a 24 hour history of fever, headache and neck 
stiffness. He is on antiretroviral therapy, his most recent CD4 was 550 cells/µL and he reports 
having attended a sex party four weeks ago. Syphilis serology identifies positive EIA and 
TPHA but negative VDRL. Lumbar puncture reveals WBC of 12 cells/µL, predominantly 
lymphocytes, and CSF VDRL is negative. 
 
The bloods suggest either primary syphilis or a previously treated infection. Correlating this 
with previous serology and a good history should help to establish which. If primary syphilis 
is likely then this event signifies neuroinvasion of T.pallidum which is often cleared 
spontaneously by patients but given the symptoms and pleocytosis he should be treated with a 
neuropenetrative penicillin regimen. If this is not a case of primary syphilis then other causes 
of his symptoms and pleocytosis, such as a viral meningitis, should be sought. 
 
Case Three: 
A 60 year old HIV positive man with a CD4 count of 623 cells/µL and on effective 
antiretroviral therapy presents to a specialist HIV and neurology clinic with a history of 
cognitive decline. His bloods reveal a positive EIA and TPHA but negative VDRL. He does 
not recall receiving treatment for syphilis in the past. His MRI shows generalized atrophy. 
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Lumbar puncture identified WBC of 8 cells/µL and all other tests including CSF-VDRL are 
negative.  
 
This man has certainly had syphilis in the past and he may well have been treated without 
remembering. However, his bloods may indicate late-latent infection which may be the cause 
of his cognitive impairment. A negative CSF-VDRL does not rule out this diagnosis and he 
should be treated for neurosyphilis whilst continuing other investigations for his cognitive 
decline. 
 
KEY POINTS FOR NEUROLOGISTS 
1. Always consider syphilis in the differential diagnosis of neurological presentations in 
HIV positive individuals. 
2. In HIV positive individuals with serological evidence of syphilis always take a 
detailed history and examine for neurological signs. 
3. Lumbar puncture should be considered in all patients with HIV and syphilis co-
infection with neurological signs or if the CD4 count is <350 cells/µL, serum 
RPR/VDRL titer is ≥1:32, or they are not on antiretroviral therapy. 
4. If CSF-VDRL is negative, still consider neurosyphilis in patients with neurological 
signs and/or a CSF WBC >10 cells/µL in treated HIV infection or >20 cells/µL in 
untreated infection. 
5. Always perform a HIV test if a patient who is diagnosed with neurosyphilis is not 
known to be HIV positive. 
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Figures Legend 
Figure 1: Number of syphilis infections in England between 2007 and 2016(4) 
Figure 2: MRI T2 signal alteration in the right cerebral peduncle (arrowed) of a patient with 
meningovascular neurosyphilis(40).  
Figure 3: Cerebral infarction in a 22-year old HIV- positive patient with neurosyphilis. T1-
weighted image with gadolinium(40).  
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